Abd-Elsalam S - Search Results

1

Acceleration of Wound Healing in Diabetic Rats through a Novel 3D Organo-Hydrogel Nanocomposite of Polydopamine/TiO2 Nanoparticles and Cu (PDA-TiO2@Cu).

Elekhtiar SA, Abo Gazia MM, Helal AI, Mahfouz H, El-Kemary NM, Abd-Elsalam S, Elksass S, Alkabes HA, El-Kemary M, Abd-Elsalam MM. Elekhtiar SA, et al. Among authors: abd elsalam s. Endocr Metab Immune Disord Drug Targets. 2024 Apr 26. doi: 10.2174/0118715303280532240415094718. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38676522

2

Gastroprotective effects of montelukast and Nigella sativa oil against corticosteroid-induced gastric damage: they are much more than antiasthmatic drugs.

Rizk FH, Ibrahim MAA, Abd-Elsalam MM, Soliman NA, Abd-Elsalam SM. Rizk FH, et al. Can J Physiol Pharmacol. 2017 Jun;95(6):714-720. doi: 10.1139/cjpp-2016-0374. Epub 2017 Feb 10. Can J Physiol Pharmacol. 2017. PMID: 28187265

3

Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.

Abdelmoemen G, Khodeir SA, Zaki AN, Kassab M, Abou-Saif S, Abd-Elsalam S. Abdelmoemen G, et al. Endocr Metab Immune Disord Drug Targets. 2019;19(2):185-188. doi: 10.2174/1871530318666180716100543. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30009716

4

Predicting Esophageal Varices in Cirrhotic Hepatitis C Virus Patients Using Noninvasive Measurement of Insulin Resistance Variables.

Wasfy E, Elkassas G, Elnawasany S, Elkasrawy K, Abd-Elsalam S, Soliman S, Badawi R. Wasfy E, et al. Endocr Metab Immune Disord Drug Targets. 2018;18(6):573-580. doi: 10.2174/1871530318666180803120428. Endocr Metab Immune Disord Drug Targets. 2018. PMID: 30073932

5

Heat shock protein 47 as indispensible participant in liver fibrosis: Possible protective effect of lactoferrin.

Rizk FH, Sarhan NI, Soliman NA, Ibrahim MAA, Abd-Elsalam M, Abd-Elsalam S. Rizk FH, et al. IUBMB Life. 2018 Aug;70(8):795-805. doi: 10.1002/iub.1884. Epub 2018 Aug 9. IUBMB Life. 2018. PMID: 30092114 Free article.

6

Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt.

Badawi R, Alboraie M, Abd-Elsalam S, Abourahma MZ, Ramadan HK, Ahmed OA, Fouad MHA, Soliman S, Mohareb DA, Haydara T, Alnabawy SM, El Kassas M. Badawi R, et al. Endocr Metab Immune Disord Drug Targets. 2019;19(7):1005-1011. doi: 10.2174/1871530319666190204154830. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30727931 Clinical Trial.

7

Role of Both Protein C and Antithrombin III as Predictors of Stage of Liver Disease in Chronic Viral Hepatitis B or C Infected Patients.

Abo-Elenein AM, Mabrouk MM, Abou-Saif S, Saeed OM, Khodeir S, Elkadeem M, Elashry H, Haydara T, Zaghloul MS, Seleem WM, Elshweikh SA, Abd-Elsalam S. Abo-Elenein AM, et al. Endocr Metab Immune Disord Drug Targets. 2020;20(1):112-117. doi: 10.2174/1871530319666190529092555. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31142255

8

Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.

Soliman H, Ziada D, Salama M, Hamisa M, Badawi R, Hawash N, Selim A, Abd-Elsalam S. Soliman H, et al. Endocr Metab Immune Disord Drug Targets. 2020;20(1):104-111. doi: 10.2174/1871530319666190826150344. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31448717

9

The Effect of Stem Cell Transplantation Therapy for Post Viral Chronic Liver Cell Failure on Associated Type II Diabetes Mellitus: A Pilot Study.

Haydara T, Gabr M, Abofreikha M, Bahnasy A, Salama H, Elhendawy M, Elkadeem M, Abd-Elsalam S. Haydara T, et al. Endocr Metab Immune Disord Drug Targets. 2020;20(6):903-916. doi: 10.2174/1871530319666191202125402. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31789137 Clinical Trial.

10

The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.

Soliman H, Ziada D, Hamisa M, Badawi R, Hawash N, Salama M, Abd-Elsalam S. Soliman H, et al. Endocr Metab Immune Disord Drug Targets. 2022;22(1):100-107. doi: 10.2174/1871530321666210125125500. Endocr Metab Immune Disord Drug Targets. 2022. PMID: 33550979

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page